We are live on ! Find out more
QNCX icon

Quince Therapeutics
QNCX

41 hedge funds and large institutions have $4.68M invested in Quince Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

0.01% less ownership

Funds ownership: 0.08% → 0.07% (-0.01%)

7% less funds holding

Funds holding: 44 → 41 (-3)

39% less capital invested

Capital invested by funds: $7.71M → $4.68M (-$3.03M)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
41
Holders Change
-3
Holders Change %
-6.82%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
10
Reduced
9
Closed
5
Calls
$12K
Puts
–
Net Calls
+$12K
Net Calls Change
-$8K

Top Buyers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
+$309K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$75K
3
Citadel Advisors
Citadel Advisors
Florida
+$66.3K
4
ACM
ADAR1 Capital Management
Texas
+$59.8K
5
BlackRock
BlackRock
New York
+$20.6K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$1.31M
2
SI
Scharf Investments
California
-$96.5K
3
Renaissance Technologies
Renaissance Technologies
New York
-$32.7K
4
IC
IEQ Capital
California
-$23.9K
5
Millennium Management
Millennium Management
New York
-$15.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$7.21K +$2.17K +12 +33%
Morgan Stanley
27
Morgan Stanley
New York
$6.39K +$181 +1 +2%
Citigroup
28
Citigroup
New York
$3.87K – – –
Group One Trading
29
Group One Trading
Illinois
$1.2K – – –
Simplex Trading
30
Simplex Trading
Illinois
$1K -$2.35K -13 -54%
UBS Group
31
UBS Group
Switzerland
$360 -$181 -1 -33%
JP Morgan Chase
32
JP Morgan Chase
New York
$352 – – –
CA
33
CoreCap Advisors
Michigan
$323 – – –
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$295 – – –
JFG
35
JDM Financial Group
Texas
$255 – – –
FP
36
Financial Perspectives
Minnesota
$233 – – –
PA
37
Parallel Advisors
California
$221 -$181 -1 -50%
Osaic Holdings
38
Osaic Holdings
Arizona
$207 – – –
Barclays
39
Barclays
United Kingdom
$75 – – –
FA
40
Financial Avengers
California
$75 – – –
WIM
41
Westside Investment Management
California
$56 – – –
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$18 – – –
SI
43
Scharf Investments
California
– -$96.5K -455 Closed
IC
44
IEQ Capital
California
– -$23.9K -113 Closed
WP
45
Westmount Partners
California
– -$10.6K -50 Closed
Fidelity Investments
46
Fidelity Investments
Massachusetts
– -$1.59K -8 Closed
Wells Fargo
47
Wells Fargo
California
– -$284 -1 Closed
1
2

QNCX Hedge Fund Activity: Q2 2024 in Review

41 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q2 2024, worth a combined $4.68M — down 39% from $7.71M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of QNCX and 2 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 10 added.

The largest buyer was HighTower Advisors, opening a new position worth an estimated $309K. The largest seller was Tang Capital Management, cutting an estimated $1.31M.

  • 41 institutional investors held Quince Therapeutics (QNCX) as of Q2 2024, down from 44 in Q1 2024.
  • Funds reported $4.68M of Quince Therapeutics stock for Q2 2024, down 39% quarter-over-quarter.
  • 2 funds opened new Quince Therapeutics positions in Q2 2024 and 5 closed out, a net change of -3 holders.
  • The largest Quince Therapeutics buyer in Q2 2024 was HighTower Advisors, an estimated $309K added.
  • The largest Quince Therapeutics seller in Q2 2024 was Tang Capital Management, an estimated $1.31M sold.

Based on aggregated 13F filings for Q2 2024.